With digital therapeutics marking a decade of market availability, the DTx industry is demonstrating a strong record of clinical impact. As industry momentum increases, scalability hinges on the adoption of harmonized evaluation frameworks to streamline the process of bringing safe and effective digital therapeutics into clinical use globally.
To embark on the next era of industry growth, DTA released the “DTx Value Assessment & Integration Guide”- a first ever industry framework for the evaluation and implementation of digital therapeutics. (Available here.)
The Guide provides a tool for payors, policymakers, clinicians, and other healthcare decision makers (HCDMs) to use in assessing baseline information about DTx products, their value, and their impact in real-world settings. It was developed through a collaborative two-year process incorporating insights from DTA members, payors, clinicians, and other key stakeholders to ensure applicability across settings.
As a part of the launch, DTA hosted a public webinar to discuss the release of the “DTx Value Assessment & Integration Guide” with panelists: